Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Connie A. Haley, Patricia Macias, Supriya Jasuja, Betsy A. Jones, Marie‐Claire Rowlinson, Roshni Jaimon, Pennelyn Onderko, Elaine Darnall, Maria E. Gomez, Charles A. Peloquin, David Ashkin, Neela D. Goswami
Abstract
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
Topics & Concepts
BedaquilineLinezolidRegimenMedicineTuberculosisDrugExtensively drug-resistant tuberculosisDrug resistanceFood and drug administrationInternal medicinePharmacologyMycobacterium tuberculosisBiologyMicrobiologyPathologyVancomycinGeneticsStaphylococcus aureusBacteriaTuberculosis Research and EpidemiologyMycobacterium research and diagnosisPneumonia and Respiratory Infections